JPIAMR: Network proposal call; BARDA: DRIVe Accelerator call

Dear All: I trust you are now home after ECCMID in Madrid … it was an excellent meeting. Two new funding opportunities have recently crossed my radar: brief summaries and one key link for each are here with some further details below my signature. 

  • EU JPIAMR funding call: As part of its Virtual Research Institute (VRI) initiative, JPIAMR wants to fund as many as 22 collaborative research networks.
  • US BARDA Funding Opportunity Announcement: Building on the job opportunities recently announced for its DRIVe initiative, BARDA is creating an accelerator network providing technical and business development support services to programs funded by DRIVe.

This is great to see happening! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future:

JPIAMR call for network proposals:

  • JPIAMR seeks to encourage research alignment via establishing a Virtual Research Institute in AMR – a global network connecting research performing organisations, including institutes, centres, and infrastructures.
  • In partnership with ten member countries; Canada, Egypt, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom, JPIAMR is launching the 8th joint call for transnational Networks. The total budget of the call is approximately 1.1 million Euro. This Network Call “Building the Foundation of the JPIAMR Virtual Research Institute” aims to identify research community needs and develop ideas to form the foundation for the JPIAMR-VRI
  • Up to 22 Networks will be funded with up to €50 000 each coordinator to connect experts from research performing organisations and establish expertise clusters in the AMR community.
  • The formation of larger, multi-coordinator Networks is possible according to national rules.
  • Deadline for proposals is 4 July 2018.

BARDA DRIVEe Accelerator Network: Funding Opportunity Announcement:

  • BARDA’s newest Division of Research, Innovation and Ventures (DRIVe), will stimulate public-private partnership collaborations that spur innovation and investment in health security products and technologies to repopulate the development pipeline and stimulate the public good of the nation. 
  • A key component of this is the DRIVe Accelerator Network, where accelerators work together to identify promising, innovation and then provide wraparound technical and business development support services to programs funded by DRIVe. 
  • DRIVe Accelerator Network support teams will bring together a network of multiple accelerators, building on their individual strengths and unleash them to work directly with product developers funded by DRIVe.  
  • Product development candidates that graduate from DRIVe with support of the DRIVe Accelerator Network will be better positioned for advanced R&D investment, clinical development, and commercialization. 
  • The deadline for proposals is 17 May 2018.

Upcoming meetings of interest to the AMR community:


EPA (part 2, streptomycin!) / $104m ARPA-H AMR project

Dear All (OK, so now it’s 5 newsletters in as many days … exciting times … can’t keep up!), Two follow-up items today. First, yesterday’s newsletter about EPA’s concept note regarding AMR risks of pesticides prompted one of your fellow readers to remind me about this lawsuit filed with the U.S. Court of Appeals, Ninth Circuit: Case

BARDA Medical Countermeasures BAA: Substantial updates

Dear All (and yes, back-to-back newsletters … lots of action this week!): BARDA have today released a new version of their long-running BAA (Broad Agency Announcement, formerly BAA-18-100-SOL-00003) that seeks medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The new BAA is BAA-23-100-SOL-00004 and has been completely reorganized and

Appropriate duration of antimicrobial dosing in food animal care

Dear All,  I’ve watched with interest the way that FDA’s CVM (Center for Veterinary Medicine) has been working steadily with the veterinary community as a whole to reduce antibiotic resistance pressure by improving the way antibiotics are used in animal care. The titles of these prior newsletters give you a feel for some aspects of

Scroll to Top